We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Solutions Designed for Labs to Reduce Costs and Improve Productivity Showcased at the AACC Expo

By LabMedica International staff writers
Posted on 02 Aug 2013
Print article
Abbott (Abbott Park, IL, USA) features solutions to help labs prepare for the evolving healthcare environment. US healthcare providers are playing an increasingly important role in clinical labs to prevent medical errors, lower readmission rates, and improve patient care. Abbott showcased solutions designed to meet the needs of its lab customers while reducing costs and improving productivity at the American Association for Clinical Chemistry (AACC) annual meeting and clinical lab expo, July 28–August 1, 2013 in Houston (TX, USA).

Abbott also featured a variety of its solutions, including the first US Food and Drug Administration (FDA; Silver Spring, MD, USA)- approved genotyping test for hepatitis C (HCV), the RealTime HCV Genotype II test; the FDA-cleared FreeStyle Precision Pro Blood Glucose and β-Ketone Monitoring System; as well as the Accelerator a3600, a laboratory automation track system.

In addition, Abbott also showcased the company’s approach to customer-focused innovation through its program called "Factoring in the Human." On its recently launched Web site (please see Related Links below). Abbott shares the company’s focus on human factor principles and customer-centric approaches to influence product design. Laboratory professionals are encouraged to visit the website to learn more.

"Clinical laboratories are looking for the right solutions to successfully address the complexities and opportunities presented by the changing healthcare environment," said Greg Ahlberg, divisional vice president, US Commercial Operations, Diagnostics, Abbott. "Abbott has one of the broadest and most flexible portfolios available today to help labs drive efficiency and optimization, leading to improved patient care."

More than 30 scientific posters and/or oral presentations related to Abbott’s solutions will be presented during the AACC program. Seventeen posters cover cardiac markers and 13 focus on the performance of several clinical chemistry assays as well as on important areas, such as transplant, endocrine, metabolic, and congenitals.

Related Links:

Abbott
Abbott - Factoring the Human
US Food and Drug Administration


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.